First: Zanrong Pharmaceutical S. and Round financing of nearly 20 million U.S. dollars, the first new anti-cancer drug into clinical research.

Guide: Tens of millions of dollars investment, committed to new drug clinical research, burning money has just begun! Arterial network (microsignal: vcbeat) was informed for the first time, located in Shanghai and Suzhou, Zanrong Pharmaceutical Technology Co., Ltd. ("Zanrong Pharmaceuticals") announced that it has completed nearly 20 million U.S. dollars of A-plus round financing, the proceeds of the financing are mainly used to promote the company's core projects in China and the United States to carry out clinical first-phase trials, promote the remaining projects to complete IND declaration and screening of clinical candidates, in addition to the company will also raise funds for new projects, the development of the company's development and diversification of the company's development.
this round of financing by Sherpa Investment and Qiming Ventures co-led investment, power-side capital and investment.
, Qiming Ventures and Power Capital are the original investors of Zanrong Pharmaceuticals, and Sherpa Investment is a new investor.
The historical financing situation of Zanrong Pharmaceuticals from the historical financing situation of Zanrong Pharmaceuticals can be seen, since the establishment of the company in 2018, Zanrong Pharmaceuticals has completed three consecutive financings in two years, and there are deep-cultivated medical and health investment institutions continue to invest. What is the charm of
Zanrong Pharmaceuticals to attract the continued attention of capital? Arterial Network interviewed the company's founder, chairman and chief executive officer, Dr. Cheng Ziqiang and co-founder and chief scientific officer Dr. Zhou Ding, to find out to readers.
star big pharmaceutical company senior pharmaceutical research experts set up, per capita nearly 20 years of industry deep-cultivation experience Zanrong Pharmaceutical Chairman, CEO Cheng Ziqiang is the University of Iowa Pharmaceuticals (DMPK) Ph.D., Purdue University in the United States, the United States has accumulated nearly 20 years of pharmaceutical industry experience in clinical drug research and development, has served as an internationally renowned pharmaceutical company AstraZeneca and GlaxoMark Pharmaceutical Metabolistics (DMPK) Director.
, Chairman and CEO of Zanrong Pharmaceuticals (CEO) Dr. Cheng Ziqiang, as the head of AstraZeneca's global research and development program, successfully led the first-in-class project from target validation to early clinical, and as a core scientist successfully pushed an innovative drug for lung cancer brain metastasis to clinical phase III. As one of the world's Toptalent,
has been sent by the company to Tsinghua University School of Economics and Management, China Europe International Business School, MIT Sloan Business School to study in a comprehensive range of strategic and managerial skills beyond the status of scientists. Dr. Zhanrong Pharmaceuticals Chief Scientific Officer (CSO) Of
, Dr. Zhanrong Pharmaceutical Chief Scientific Officer (CSO) Zhou Ding is a Ph.D. and Master of Medicine in Pharmaceutical Chemistry at the University of Leuven, Belgium, completing a postdoctoral degree at the Center for Drug Design at Minnesota State University in the United States, and was a neuronV at GlaxoSmithKline China Innovation Center Head of Drug Chemistry in PoC Department, has accumulated nearly 20 years of experience in drug design and development, presided over a number of pilot compound selection and optimization, candidate drug screening and preclinical evaluation, and has solved many clinical candidated drug DMPK problems, especially in how to design and evaluate compounds into the brain. Dr.
Zhou Ding successfully designed and screened eight "first-in-class" projects for clinical studies, of which Ivosidenib has been approved by the FDA for listing in 2017, and Vorasidenib has now entered the U.S. Phase III Clinical (Glioma).
in addition to the founding team, Zanrong Pharmaceuticals also gathered a number of senior experts in the pharmaceutical industry, the company's chief medical officer is more than 25 years of clinical development medical experience of chinese-Americans, before joining the company, she has served as the United States Pfizer, Sanofi senior medical director, but also served as a Chinese biotech company's Chief Medical Officer (CMO);
in addition, Zanrong Pharmaceutical's clinical team and pre-clinical team are composed of the core staff of well-known pharmaceutical companies in the industry such as glaxoSmithKline, Novartis and Pharmaceutical Sinbet, with more than 10 years of experience in the medical industry per capita, ensuring the hard strength and execution of the team.
leads the tumor brain metastasis high barrier track, two years from zero into clinical trials two years three times to obtain financing, the capital is in zanrong medicine has significant differentiation and international competitiveness of the project and high implementation ability of the team. Dr. Cheng Ziqiang,
, revealed to Arterial Network that there are currently five core pipelines under Zanrong Pharmaceuticals, of which the fastest progress has entered the first phase of clinical phase in China and the United States.
since the company was established in 2018, in just two years, Zanrong Pharmaceuticals has completed the independent design of innovative drugs to enter clinical trials, in the industry to stabilize, while maintaining the "small step fast running" financing rhythm.
for obtaining this round of financing, Dr. Zhou Ding from the company's pipeline layout of the interpretation: "differentiated projects and unmet clinical needs are the main reasons for Zanrong Pharmaceuticals to obtain capital recognition."
our five pipelines based on pharmacokinetics (DMPK), from the distribution of drugs, metabolism, and absorption, focusing on the discovery and solution of existing clinical compounds outstanding problems, to ensure the differentiation of projects.
in addition, investors are looking at our project to solve the differentiation problem is precisely the founding team is good at the field, which ensures that the project in the implementation process can successfully achieve this differentiation, such as the company is now leading the core project is for clinically unmet brain transfer treatment needs, which just match our long-term accumulation of brain compound design and evaluation experience.
" of the five core pipelines built by Zanrong Pharmaceuticals, most notably the company's innovative pipeline for breast cancer brain metastasis, the company's fastest-growing clinical pipeline.
at present, breast cancer brain metastasis in clinical treatment has no standard treatment drugs on the market, the existing treatment is limited to whole-brain radiotherapy or stereotactic radiation therapy, patients have a very short survival.
clinical urgent need to meet the strong survival desire of patients with breast cancer and other effective treatment drugs, which has also become the source of Zanrong Pharmaceutical development of this innovative drug.
Zanrong Pharmaceuticals has been praised by top clinical experts in China and the United States, including Harvard Medical School, Massachusetts General Hospital, Duke University and Oncology Hospital of the Chinese Academy of Medical Sciences.
the project has only two years from self-designing compounds to obtaining clinical approvals in China and the United States, why is there such a high level of efficiency and execution? Dr Cheng shared a few experiences: "The first principle we implement the project is 'proactive', which is to plan ahead and plan ahead."
- for example, the company was founded on March 8, 2018, and Dr. Zhou and I visited THE CRO, which makes animal models, the day after the company was founded.
the VICE PRESIDENT of the CRAske asked when our company was founded. We said yesterday.
she asked you if you had any compounds? Do compounds have offsome data? We said no.
she looked puzzled, and what are you doing?
we told her that when the animal model sat in 4-5 months, we would definitely have the compounds and data.
in our company, such examples can be said to be commonplace, innocousm.
", the second principle is in the company's operations and project progress, 95% of the time to do important but not urgent things, to do orderly and orderly work.
but there is a real emergency, we need to go to the battlefield bayonet, in order to have wisdom and energy to deal with.
for example, this time our first project IND declaration stage is catching up with the most serious period of China's epidemic, in the case of elevator suspension, we shoulder-to-shoulder, the declaration materials from the stairs to the downstairs, good in Shunfeng is still running, the declaration materials were sent to the capital of the motherland Beijing, although encountered resistance, still submitted the IND application on time.
third reason is due to the return of Dr. Zhou and I for 10 years, the pharmaceutical industry involved in the industrial chain of THE CRO is very aware, the decisive adoption of the VIC (Venture - IP-CRO) model, improve the efficiency of the company's operations and project research and development.
we have a CRO "popular review" in our mind, which restaurant (CRO) is a handy dish, and even the exact name of which chef (CRO team) to do for us, which allows us to get the best service and develop with CRO.
the fourth reason is also the most important reason, team members are basically I and Dr. Zhou have worked together to fight the old colleagues, each excellent in the selection, to one as ten, with a strong ability to learn from one and three.
the past two years, we work together, nervous and orderly, upand, matching each other, the execution of the explosive meter.
our company is a high-speed rail model, unlike the traditional green train only by the locomotive (founder), each employee is like the high-speed rail each car has its own power. Dr Cheng Ziqiang,
, added: "Although we are start-ups, we regulate ourselves by international pharmaceutical companies, so the filings are fully prepared to be approved by U.S. and Chinese regulators, with NMPA approval in just 45 working days(usually 60 working days).
project obtains the FDA clinical approval at one time at about the same time.
the current clinical trial of the project has begun in both China and the United States.
", Dr. Zhou Ding is confident about the layout and advancement of the company's existing pipeline projects: "In addition to developing innovative drugs for brain metastasis for breast cancer, Zanrong Pharmaceuticals designs small molecule anti-tumor drugs from a differentiated perspective to address the pain points of existing clinical drugs, and strives to achieve 'bestinclass) or 'first-in-class'.
now, the second project clinical candidate has been screened and INDenableingstudies has already begun, with three differentiated projects also in the lead-and-lead phase, with the aim of getting clinical approval next year.
," he added, "Although the company's projects are self-developed, starting from scratch, but after two years of careful layout and efforts, the company's product pipeline and business operations have made significant progress, the company will actively engage in deep cooperation with multinational pharmaceutical companies."
" it is understood that Zanrong Pharma currently has three international patent PCT applications.
participated in the National Innovation and Entrepreneurship Competition in 2019, Zanrong Pharmaceuticals emerged from 3,700 biopharmaceutical enterprises and won the second place in the start-up group.
the company was also awarded the "Investment Value Of the Year Award" by the Shanghai Science and Technology Commission, as well as the "Zhangjiang Innovation Vitality Award", "Suzhou Entrepreneurship Leader", "Suzhou Innovation Leader" and other honors. "Zanrong Pharmaceuticals' product pipelines are starting point for drug dMPK problems, and many high-potential targets are therefore tapped to a deeper clinical value that can benefit more patients," said Yu, managing partner of
for investing in Zanrong Pharmaceuticals, lead investor Sherpa Investment.
team has been established in just two years to obtain the first product of the Clinical Approval sand, during the outbreak is still able to complete the pipeline product milestone in accordance with the established schedule, which reflects the high efficiency. We were impressed by the global differentiated innovation and team execution of
's Zanrong products. "Zanrong Pharma has a "exemplary" founding team with deep insight into the unmet medical needs in the market, so it is internationally best-performing, carefully strategically laid out, while being able to combine internal and external capabilities to promote implementation, 2 years has seen its product pipeline with obvious differentiation and international competitiveness, we believe that Zanrong Pharmaceuticals will continue to usher in important milestones from China.
"
" old investor Taifu Capital Partner Li Ming said: "Zanrong Pharmaceutical in the field of small molecule new drug development, has a unique development platform, the products developed to meet the current clinical practice of the huge unmet demand, very competitive potential."
as a co-founder of Zanrong Pharmaceuticals, Taifu Capital has witnessed the very efficient cooperation between Dr. Cheng Ziqiang and Dr. Zhou Ding, as well as the team's efforts.
we are very grateful for the further support of Qiming Ventures and Sherpa Investments and hope that we and our team will work together to bring our products to market as soon as possible for the benefit of patients. "The founding team of Zanrong Pharmaceuticals is highly complementary in experience, has a clear strategic positioning, and chooses to develop differentiated and globally competitive products for unmet clinical needs," said Shi Yongling, a partner at
".
Juming Ventures, as the a-turned-investor of Zanrong Pharmaceuticals A, has witnessed the company's continuous innovation capability in promoting the first product from discovery to clinical development until it enters clinical development in China, and the company's team has continued to improve as the project advances from the pre-clinical discovery phase to the clinical phase.
we believe that Zanrong Pharmaceuticals will grow into an influential small molecule anti-tumor innovation drug company in the world. "As an angel investor of Zanrong Pharmaceuticals, Power Capital has witnessed the company's rapid growth throughout 2018," said Bai Wei, a partner at
".
company's product pipeline from a differentiated point of view, not chasing hot targets, but another way, from the team's most experienced areas to start the development of innovative drugs, and in practice and constantly verified.
more than two years, Zanrong pharmaceutical team left me the deepest impression, is constantly exceeded my expectations.
therefore, the team can continue to be recognized by new investors, power side capital also three consecutive rounds of continuous plus-size investment Zanrong Pharmaceuticals, hope that the next company developed drugs can benefit patients as soon as possible.
"About Sherpa Investment Sherpa Investment is a professional, focused dual-currency healthcare investment fund established in 2018.
core members of the team have worked together for more than 10 years and have a wealth of investment experience and outstanding historical performance in China's healthcare industry.
team is determined to be the professional guide behind the medical technology climbers, helping entrepreneurs to climb the pinnacle of their careers.
Sherpa investment team has invested in a number of industry leaders on key tracks such as life technology, medicine, device diagnostics and medical services, and is one of their earliest and most important investors.
, Qiming Ventures was established in 2006 and has offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area.
currently manages Qiming Ventures.